Overview

Benign Prostatic Hyperplasia in Taiwan

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective: - To assess the sexual function of Benign Prostatic Hyperplasia patients Secondary Objective: - To evaluate the association between Lower Urinary Tract Symptoms severity and sexual disorders - To compare the sexual function, urinary symptoms and Quality of Life of Benign Prostatic Hyperplasia patients on XATRAL 10mg OD among the different regions - To correlate the Male Sexual Health Questionnaire(MSHQ) and 5-item version of the International Index of Erectile Function (IIEF-5) - To assess the onset of action of XATRAL 10mg OD - To assess the peak urinary flow rate - To assess the safety and the tolerability of XATRAL 10mg OD
Phase:
N/A
Details
Lead Sponsor:
Sanofi
Treatments:
Alfuzosin